Progress of Nanoparticles in the Treatment of Cancers

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".

Deadline for manuscript submissions: 20 June 2026 | Viewed by 1433

Special Issue Editors


E-Mail Website
Guest Editor
Department of Dermatology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Interests: radiation; DNA damage; skin cancer (melanoma and non-melanoma); immunosuppression
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Microbiology, Immunology & Genetics, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
Interests: cancer; cancer biology; cancer genetics; DNA replication; yeast genetics; S. pombe; S. cerevisiae; human breast cancer; checkpoints; genomic instability; mTOR complex

Special Issue Information

Dear Colleagues,

The field of nanotechnology has revolutionized the landscape of cancer research and treatment, offering unprecedented opportunities to overcome the limitations of conventional therapies. At the forefront of this revolution are nanoparticles, which have emerged as versatile tools for precise and targeted delivery of therapeutic agents to cancer cells. This Special Issue titled "Progress of Nanoparticles in the Treatment of Cancers" aims to provide an in-depth exploration of the latest advancements in the use of nanoparticles to manipulate cellular and molecular mechanisms underlying cancer biology and pathophysiology.

Recent years have witnessed significant progress in understanding the complex interplay between cancer cells and their microenvironment, as well as the intricate signaling pathways that drive cancer initiation, progression, and metastasis. Nanoparticles, with their unique physicochemical properties and tunable surface chemistry, offer a powerful platform for interfering with these processes at the cellular and molecular levels. From drug delivery to gene therapy, from photothermal ablation to immunotherapy, nanoparticles are being harnessed to disrupt cancer-promoting signaling pathways, induce apoptosis, and modulate the immune response against cancer.

This Special Issue offers a comprehensive overview of the current state of the art in nanoparticle-based cancer therapies, exploring their potential to revolutionize cancer treatment through precise manipulation of cellular and molecular mechanisms. We welcome the submission of both original research articles and comprehensive reviews and hope that the insights and findings presented here will inspire further research and development in this exciting and rapidly evolving field.

Dr. Mohammad Asif Sherwani
Dr. Nafees Ahamad
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • cancer treatment
  • cellular mechanisms
  • molecular biology
  • pathophysiology
  • drug delivery
  • drug resistance
  • immunotherapy
  • tumor microenvironment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2822 KB  
Article
Doxorubicin-Loaded Nanoparticle Treatment Enhances Diffuse Large B-Cell Lymphoma Cell Death
by Ihab Abd-Elrahman, Noha Khairi, Taher Nassar, Riki Perlman and Dina Ben Yehuda
Cells 2025, 14(17), 1334; https://doi.org/10.3390/cells14171334 - 28 Aug 2025
Viewed by 975
Abstract
Drug resistance remains a major obstacle in cancer treatment despite advances in therapeutic regimens. To address this, we explored the potential of Doxorubicin (Dox) delivery in poly (lactide-co-glycolic acid) (PLGA) nanoparticles to enhance Diffuse large B-cell lymphoma (DLBCL) cell death. This research investigates [...] Read more.
Drug resistance remains a major obstacle in cancer treatment despite advances in therapeutic regimens. To address this, we explored the potential of Doxorubicin (Dox) delivery in poly (lactide-co-glycolic acid) (PLGA) nanoparticles to enhance Diffuse large B-cell lymphoma (DLBCL) cell death. This research investigates the potential of Doxorubicin and advanced delivery methods. We used PLGA nanoparticles with Oleyl cysteineamide (OCA); its amphiphilic nature enables interfacial anchoring and thiol surface functionalization of PLGA NPs. Compared to PLGA-NPs, PLGA-OCA-NPs enhance immunity and induce tumor cell death. They also show significant apoptotic cell death and induced immune responses in DLBCL mouse models. Dox-conjugated PLGA-OCA-NPs (DOX-OCA) exhibit significant in vitro and in vivo anticancer activity compared to free DOX, showing remarkable antitumor effects with reduced systemic toxicity in mouse models. Our findings underscore the promising potential of PLGA-OCA-NPs in DLBCL treatment, offering a hopeful future in cancer therapy. This innovative delivery system offers enhanced immune responses and effectively addresses toxicity concerns, marking a significant step forward in cancer therapy. Full article
(This article belongs to the Special Issue Progress of Nanoparticles in the Treatment of Cancers)
Show Figures

Figure 1

Back to TopTop